Zhen Yu

Dr. Zhen Yu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Experimental Eye Research
Verified
Journal Article
Closed access
SMShisi Ma
Shisi Ma
ZYZhen Yu
Zhen Yu
SFSongfu Feng
Songfu Feng
HCHuijie Chen
Huijie Chen
HCHaiyan Chen
Haiyan Chen
XLXiaohe Lu
Xiaohe Lu

17 May 2020 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
ZYZhen Yu
Zhen Yu
SMShisi Ma
Shisi Ma
MWMengfan Wu
Mengfan Wu
HCHuan Cui
Huan Cui
RWRong Wu
Rong Wu
SFSongfu Feng
Songfu Feng

6 October 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MWMengfan Wu
Mengfan Wu
DMDany Y. Matar
Dany Y. Matar
ZYZhen Yu
Zhen Yu
ZCZiyu Chen
Ziyu Chen
SKSamuel Alfons Christoph Knoedler
Samuel Alfons Christoph Knoedler
Adriana C PanayiAdriana C Panayi
Adriana C Panayi
Scarring is associated with significant morbidity. The mechanical signaling factor yes-associated protein (YAP) has been linked to Engrailed-1 (En1)-lineage positive fibroblasts (EPFs), a pro-scarring fibroblast lineage, establishing a connection between mechanotransduction and fibrosis. In this study, we investigate the impact of micromechanical forces exerted through negative pressure wound therapy (NPWT) on the pathophysiology of fibrosis. Full-thickness excisional dorsal skin wounds were created on diabetic (db/db) mice which were treated with occlusive covering (control) or NPWT (continuous, −125 mmHg, 7 days; NPWT). Analysis was performed on tissue harvested 10 days after wounding. NPWT was associated with increased YAP (p = 0.04) but decreased En1 (p = 0.0001) and CD26 (p < 0.0001). The pro-fibrotic factors Vimentin (p = 0.04), α-SMA (p = 0.04) and HSP47 (p = 0.0008) were decreased with NPWT. Fibronectin was higher (p = 0.01) and collagen deposition lower in the NPWT group (p = 0.02). NPWT increased cellular proliferation (p = 0.002) and decreased apoptosis (p = 0.03). Western blotting demonstrated increased YAP (p = 0.02) and RhoA (p = 0.03) and decreased Caspase-3 (p = 0.03) with NPWT. NPWT uncouples YAP from EPF activation, through downregulation of Caspace-3, a pro-apoptotic factor linked to keloid formation. Mechanotransduction decreases multiple pro-fibrotic factors. Through this multifactorial process, NPWT significantly decreases fibrosis and offers promising potential as a mode to improve scar appearance.

23 November 2021 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
ZYZhen Yu
Zhen Yu
NENikolaos E. Efstathiou
Nikolaos E. Efstathiou
VCVictor S. M. C. Correa
Victor S. M. C. Correa
XCXiaohong Chen
Xiaohong Chen
KIKenji Ishihara
Kenji Ishihara
DVDemetrios G. Vavvas
Demetrios G. Vavvas
Ultraviolet (UV) is one of the most energetic radiations in the solar spectrum that can result in various tissue injury disorders. Previous studies demonstrated that UVA, which represents 95% of incident photovoltaic radiation, induces corneal endothelial cells (CECs) death. Programmed cell death (PCD) has been implicated in numerous ophthalmologic diseases. Here, we investigated receptor-interacting protein 3 kinase (RIPK3), a key signaling molecule of PCD, in UVA-induced injury using a short-term corneal endothelium (CE) culture model. UVA irradiation activated RIPK3 and mediated necroptosis both in mouse CE and primary human CECs (pHCECs). UVA irradiation was associated with upregulation of key necroptotic molecules (DAI, TRIF, and MLKL) that lie downstream of RIPK3. Moreover, RIPK3 inhibition or silencing in primary corneal endothelial cells suppresses UVA-induced cell death, along with downregulation of MLKL in pHCECs. In addition, genetic inhibition or knockout of RIPK3 in mice (RIPK3K51A and RIPK3−/− mice) similarly attenuates cell death and the levels of necroptosis in ex vivo UVA irradiation experiments. In conclusion, these results identify RIPK3, not RIPK1, as a critical regulator of UVA-induced cell death in CE and indicate its potential as a future protective target.

12 December 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
ZYZhen Yu
Zhen Yu
VCVictor S. M. C. Correa
Victor S. M. C. Correa
NENikolaos E. Efstathiou
Nikolaos E. Efstathiou
HAHenar Albertos-Arranz
Henar Albertos-Arranz
XCXiaohong Chen
Xiaohong Chen
DVDemetrios G. Vavvas
Demetrios G. Vavvas
Ultraviolet light A (UVA) is the only UV light that reaches the retina and can cause indirect damage to DNA via absorption of photons by non-DNA chromophores. Previous studies demonstrate that UVA generates reactive oxygen species (ROS) and leads to programmed cell death. Programmed cell death (PCD) has been implicated in numerous ophthalmologic diseases. Here, we investigated receptor interacting protein 1 and 3 (RIPK1 and RIPK3) kinases, key signaling molecules of PCD, in UVA-induced photoreceptor injury using in vitro and ex vivo models. UVA irradiation activated RIPK3 but not RIPK1 and mediated necroptosis through MLKL that lie downstream of RIPK3 and induced apoptosis through increased oxidative stress. Moreover, RIPK3 but not RIPK1 inhibition suppresses UVA-induced cell death along with the downregulation of MLKL and attenuates the levels of oxidative stress and DNA fragmentation. In conclusion, these results identify RIPK3, not RIPK1, as a critical regulator of UVA-induced necroptosis cell death in photoreceptors and highlight RIPK3 potential as a neuroprotective target.

8 May 2025 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
ZYZhen Yu
Zhen Yu
MWMengfan Wu
Mengfan Wu
YTYuFei Tao
YuFei Tao
ZHZihan Huang
Zihan Huang
MYMingmin Yang
Mingmin Yang
NFNing Fan
Ning Fan
To assess the effectiveness of minimally invasive glaucoma surgery (MIGS) as monotherapy, or in combination with phacoemulsification, in the management of normal tension glaucoma (NTG). A systematic literature review and meta-analysis were conducted. The literature search was performed using four electronic databases, including Pubmed, Embase, Web of science, and Cochrane Central Register of Controlled Trials, to identify studies evaluating the efficacy of MIGS on patients with NTG, published from October 1, 2019 to October 1, 2024. The articles meeting our inclusion criteria were independently screened and assessed by three reviewers. Effect estimates associated with NTG were pooled and evaluated via meta-analysis. The articles retrieved from the databases were systematically analyzed using Citespace 6.2.R3. A total of 11 English-language studies involving 413 eyes from 327 NTG patients were included. Follow-up ranged from 6 to 60 months. MIGS alone reduced IOP by 2.62 mmHg (95% CI: -3.70 to -1.54; Z = 4.77, P < 0.00001), while MIGS with cataract surgery reduced IOP by 2.09 mmHg (95% CI: -2.83 to -1.35; Z = 5.53, P < 0.00001). The number of IOP-lowering medications decreased by 1.47 with MIGS alone (95% CI: -2.16 to -0.77; Z = 4.07, P < 0.0001) and by 1.13 with combined surgery (95% CI: -1.75 to -0.52; Z = 3.63, P = 0.0003). No significant differences were observed between the two surgical approaches. The meta-analysis demonstrated that either MIGS alone or combined with phacoemulsification effectively reduced the IOP and the requirement for IOP-lowering medications in NTG patients. MIGS alone or combined with phacoemulsification reduced the IOP most at 12 months, and the lowest IOP-lowering medications at 24 months in postoperative patients with NTG. Normal-tension glaucoma (NTG), a subtype of primary open-angle glaucoma (POAG), is characterized by optic nerve damage despite intraocular pressure (IOP) within the statistically normal range. Microinvasive glaucoma surgery (MIGS), with its minimal invasiveness, safety profile, and compatibility with phacoemulsification, presents a promising alternative for NTG management. However, prior evidence on the efficacy and safety of MIGS in NTG patients was limited and fragmented. This study aimed to systematically evaluate the long-term outcomes of MIGS alone or combined with phacoemulsification in reducing IOP and medication burden in NTG patients, addressing critical knowledge gaps in this understudied population. The hypothesis of this study is that Both MIGS alone and MIGS combined with phacoemulsification would achieve significant reductions in IOP and medication use in NTG patients. Combined surgery was hypothesized to offer additional benefits (e.g., addressing concurrent cataracts) without compromising safety. The meta-analysis demonstrated that MIGS alone or combined with phacoemulsification effectively reduced the IOP and the requirement for IOP-lowering medications in postoperative patients with NTG. MIGS with phacoemulsification failed to improve IOP and IOP-lowering medications more than MIGS alone. MIGS alone or combined with phacoemulsification reduced the IOP most at 12 months, and the lowest IOP-lowering medications at 24 months in postoperative patients with NTG. Both MIGS alone and combined with phacoemulsification effectively reduced IOP and medication requirements in NTG patients, with comparable efficacy. Combined surgery is advantageous for NTG patients with concurrent cataracts, preventing postoperative cataract progression and reducing reoperation risks. This study tells us that phacoemulsification alone or in combination can effectively reduce the IOP and the need for ocular hypotensive drugs in patients after NTG surgery, and reduce the occurrence of complications. This gives us more confidence to use MIGS surgery on NTG patients to achieve the purpose of anti-glaucoma treatment. In addition, the development and upgrading of existing glaucoma filtering devices will benefit more patients.